Patents by Inventor Natalia Aurrecoechea

Natalia Aurrecoechea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ADENOSINE 2 RECEPTOR ANTAGONISTS
    Publication number: 20220235056
    Abstract: The instant disclosure provides novel adenosine receptor antagonist compounds, compositions, methods of making and methods of using. In a further aspect, a method of treating a subject in need thereof, comprising administering a therapeutically effective amount of any one or more of the compounds described herein. In some embodiments, the subject has cancer and the method is a method of treating cancer.
    Type: Application
    Filed: May 1, 2020
    Publication date: July 28, 2022
    Inventors: Neel K. Anand, Natalia Aurrecoechea, Anthony James Brockway, Haiying Cai, Lin Cheng, Bo-Liang Deng, Donogh John Roger O'Mahony, Zhongxu Ren, Wen Zhang
  • Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
    Patent number: 10844076
    Abstract: The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: November 24, 2020
    Assignee: Nektar therapeutics
    Inventors: Pankaj Sharma, Vijay Kumar Khatri, Xuyuan Gu, Yuan Song, Michael Lixin Shen, Jennifer Riggs-Sauthier, Neel K. Anand, Antoni Kozlowski, Aleksandrs Odinecs, Timothy A. Riley, Zhongxu Ren, YongQi Mu, Xiaoming Shen, Xuejun Yuan, Natalia Aurrecoechea, Donogh John Roger O'Mahony, Bo-Liang Deng
  • Morphinan derivatives for the treatment of neuropathic pain
    Patent number: 10766864
    Abstract: The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of the invention, a compound according to Formula I is provided: and pharmaceutically acceptable salts thereof, wherein R1-R11 are as described herein.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: September 8, 2020
    Assignee: Nektar Therapeutics
    Inventors: Neel K. Anand, Natalia Aurrecoechea, Lin Cheng, Bo-Liang Deng, Donogh John Roger O'Mahony, YongQi Mu, Erik Krogh-Jespersen
  • DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE
    Publication number: 20190071454
    Abstract: The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.
    Type: Application
    Filed: November 6, 2018
    Publication date: March 7, 2019
    Inventors: Pankaj Sharma, Vijay Kumar Khatri, Xuyuan Gu, Yuan Song, Michael Lixin Shen, Jennifer Riggs-Sauthier, Neel K. Anand, Antoni Kozlowski, Aleksandrs Odinecs, Timothy A. Riley, Zhongxu Ren, YongQi Mu, Xiaoming Shen, Xuejun Yuan, Natalia Aurrecoechea, Donogh John Roger O'Mahony, Bo-Liang Deng
  • Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
    Patent number: 10189859
    Abstract: The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 29, 2019
    Assignee: Nektar Therapeutics
    Inventors: Pankaj Sharma, Vijay Kumar Khatri, Xuyuan Gu, Yuan Song, Michael Lixin Shen, Jennifer Riggs-Sauthier, Neel K. Anand, Antoni Kozlowski, Aleksandrs Odinecs, Timothy A. Riley, Zhongxu Ren, YongQi Mu, Xiaoming Shen, Xuejun Yuan, Natalia Aurrecoechea, Donogh John Roger O'Mahony, Bo-Liang Deng
  • MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN
    Publication number: 20180127375
    Abstract: The present invention relates to compounds and their use as ligands for mu opioid receptors. Also included are methods for preparing the compounds and pharmaceutical compositions containing the compounds. In one or more embodiments of the invention, a compound according to Formula I is provided: and pharmaceutically acceptable salts thereof, wherein R1-R11 are as described herein.
    Type: Application
    Filed: May 5, 2016
    Publication date: May 10, 2018
    Inventors: Neel K. Anand, Natalia Aurrecoechea, Lin Cheng, Bo-Liang Deng, Donogh John Roger O'Mahony, YongQi Mu, Erik Krogh-Jespersen
  • DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE
    Publication number: 20170066782
    Abstract: The instant disclosure relates to (among other things) compounds that are derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine. The compounds provided possess unique effects and differences over other phenyltriazines known in the art.
    Type: Application
    Filed: December 19, 2014
    Publication date: March 9, 2017
    Inventors: Pankaj Sharma, Vijay Kumar Khatri, Xuyuan Gu, Yuan Song, Michael Lixin Shen, Jennifer Riggs-Sauthier, Neel K. Anand, Antoni Kozlowski, Aleksandrs Odinecs, Timothy A. Riley, Zhongxu Ren, YongQi Mu, Xiaoming Shen, Xuejun Yuan, Natalia Aurrecoechea, Donogh John Roger O'Mahony
  • 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors
    Patent number: 8129396
    Abstract: 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and their salts are kinase inhibitors, useful in the treatment of cancer.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: March 6, 2012
    Assignee: Telik, Inc.
    Inventors: Natalia Aurrecoechea, Paul P. Beroza, Komath V. Damodaran, Karen Y. Pontius, Louise Robinson, Reyna J. Simon, Truong Vu, Kevin T. Weber
  • Substituted dihydroisoquinolinone compounds
    Patent number: 7858641
    Abstract: A variety of low molecular weight, guanidino-containing dihydroisoquinolinoines capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure ID where the values of the variable are defined herein.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: December 28, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Rustum S. Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith, Bryan Chang
  • Substituted pyrido [2,3-d] pyrimidinone compounds
    Patent number: 7858631
    Abstract: A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure of Formulas (IA), (IB), or (IC): where the values of the variable are defined herein.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: December 28, 2010
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Rustum S. Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith, Bryan Chang
  • SUBSTITUTED QUINAZOLINONE COMPOUNDS
    Publication number: 20100105654
    Abstract: A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structures VA, VB, VIIA and VIIB where the values of the variables are defined herein.
    Type: Application
    Filed: October 23, 2009
    Publication date: April 29, 2010
    Inventors: Rustum S. BOYCE, Natalia Aurrecoechea, Daniel Chu, Aaron Smith, Christopher R. Conlee, Brian D. Thompson, Judith de Armas Kuntz, David L. Musso, Kevin K. Barvian, Stephen A. Thomson, William R. Swain, Kien S. Du, Brian A. Chauder, Jason D. Speake, Michael J. Bishop
  • 2-[1H-Benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors
    Publication number: 20100081653
    Abstract: 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and their salts are kinase inhibitors, useful in the treatment of cancer.
    Type: Application
    Filed: September 25, 2009
    Publication date: April 1, 2010
    Inventors: Natalia Aurrecoechea, Paul P. Beroza, Komath V. Damodaran, Karen Y. Pontius, Louise Robinson, Reyna J. Simon, Truong Vu, Kevin T. Weber
  • Substituted quinazolinone compounds
    Patent number: 7625909
    Abstract: A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: December 1, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Rustum S. Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith, Christopher R. Conlee, Brian D. Thompson, Judith de Armas Kuntz, David L. Musso, Kevin K. Barvian, Stephen A. Thomson, William R. Swain, Kien S. Du, Brian A. Chauder, Jason D. Speake, Michael J. Bishop
  • Tripeptide and tetrapeptide sulfones
    Patent number: 7192918
    Abstract: Tripeptide and tetrapeptide sulfones, pharmaceutical compositions containing them, their pharmaceutical use, and their preparation, are disclosed. The compounds are useful in potentiating the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exerting toxicity in tumor cells, elevating the production of GM progenitors in bone marrow cells, stimulating the differentiation of bone marrow, mitigating the myelosuppressive effects of chemotherapeutic agents, and modulating hematopoiesis in bone marrow.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: March 20, 2007
    Assignee: Telik, Inc.
    Inventors: Steven R. Schow, Natalia Aurrecoechea
  • Tripeptide and tetrapeptide thioethers
    Patent number: 7129215
    Abstract: Tripeptide and tetrapeptide thioethers, pharmaceutical compositions containing them, their pharmaceutical use, and their preparation. The compounds are useful in potentiating the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exerting toxicity in tumor cells, elevating the production of GM progenitors in bone marrow, stimulating the differentiation of bone marrow, mitigating the myelosuppressive effects of chemotherapeutic agents, and modulating hematopoiesis in bone marrow.
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: October 31, 2006
    Assignee: Telik, Inc.
    Inventors: Natalia Aurrecoechea, Andrew B. Kelson, Robert W. Macsata, Louise Robinson, Anthony J. Sanchez, Nicholas M. Santiago, Steven R. Schow, Reyna J. Simon
  • Substituted quinazolinone compounds
    Publication number: 20060235019
    Abstract: A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure of Formulas (IA), (IB), or (IC): where the values of the variable are defined herein.
    Type: Application
    Filed: May 23, 2003
    Publication date: October 19, 2006
    Inventors: Rustum Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith
  • TRIPEPTIDE AND TETRAPEPTIDE THIOETHERS
    Publication number: 20060160749
    Abstract: Tripeptide and tetrapeptide thioethers, pharmaceutical compositions containing them, their pharmaceutical use, and their preparation. The compounds are useful in potentiating the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exerting toxicity in tumor cells, elevating the production of GM progenitors in bone marrow, stimulating the differentiation of bone marrow, mitigating the myelosuppressive effects of chemotherapeutic agents, and modulating hematopoiesis in bone marrow.
    Type: Application
    Filed: January 4, 2006
    Publication date: July 20, 2006
    Inventors: Natalia Aurrecoechea, Andrew Kelson, Robert Macsata, Louise Robinson, Anthony Sanchez, Nicholas Santiago, Steven Schow, Reyna Simon
  • Substituted quinazolinone compounds
    Patent number: 7034033
    Abstract: A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure IA, IB, or IC where the values of the variable are defined herein.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: April 25, 2006
    Assignee: Chiron Corporation
    Inventors: Rustum S. Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith, Bryan Chang
  • Substituted quinazolinone compounds
    Publication number: 20060030573
    Abstract: A variety of low molecular weight, guanidino-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases. The compounds have the structure IA, IB, or IC where the values of the variable are defined herein.
    Type: Application
    Filed: October 11, 2005
    Publication date: February 9, 2006
    Inventors: Rustum Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith, Bryan Chang
  • Substituted quinazolinone compounds
    Publication number: 20050059662
    Abstract: A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the structure IA, IB, and IC where the values of the variables are defined herein.
    Type: Application
    Filed: May 21, 2004
    Publication date: March 17, 2005
    Inventors: Rustum Boyce, Natalia Aurrecoechea, Daniel Chu, Aaron Smith, Christopher Conlee, Brian Thompson, Judith Kuntz, David Musso, Kevin Barvian, Stephen Thomson, William Swain, Kien Du, Brian Chauder, Jason Speake, Michael Bishop